Advanced Filters
noise

immune-thrombocytopenic-purpura Clinical Trials

A listing of immune-thrombocytopenic-purpura medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 90 clinical trials

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

18 years of age All Phase 1/2

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP

18 - 70 years of age All Phase 3

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

This study is intended to explore the efficacy and safety of a second course of ianalumab after experiencing treatment failure in the pivotal Primary Immune Thrombocytopenia (ITP) trials (CVAY736I12301, CVAY736Q12301) and after loss of durable response in the pivotal Warm Autoimmune Hemolytic Anemia (wAIHA) trial (CVAY736O12301).

18 - 100 years of age All Phase 2
S Shaohua Le, Master

Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children

To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate

29 - 14 years of age All Phase 4
X Xiao Hui Zhang, MD

Longitudinal Cohort of Thrombosis and Hemostasis Diseases

This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment …

years of age All Phase N/A
N Nuvig Clinical Trials

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 …

18 - 80 years of age All Phase 2
V Veronique Kouassi

Observatory of Immunological Thrombopenic Purpura in the Brest Region

Database of patients with ITP, diagnosed, treated and followed in the Brest University Hospital.

years of age All Phase N/A
H Hongmei Jing, Professor

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).

18 years of age All Phase 2

Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia

This is a single-arm, open-label,phase I clinical study to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection in treatment of refractory systemic lupus erythematosus-related immune thrombocytopenia.

18 - 70 years of age All Phase 1
M Ming Hou, PhD

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.

18 years of age All Phase 1/2

Simplify language using AI